InChord acquires U.K. based advertising agency

Share this article:
InChord Communications, the largest privately-held healthcare communications company in the world, has acquired Junction 11, a U.K.-based healthcare advertising agency.
Terms of the deal were not reported.
The acquisition will enable inChord to expand its European capability by combining Junction 11's staff and client base with its existing GSW Worldwide operation in London. GSW Worldwide is inChord's flagship advertising agency. 
The new agency will be known as GSW Worldwide/Junction 11 and will be led by Stephen Wheatley, who recently joined GSW Worldwide as president of the agency's UK operations. Wheatley most recently served as chief executive at Euro RSCG Life.  He previously held positions with TBWA, Foote Cone and Belding, Euro RSCG Group and Ogilvy and Mather Advertising. 
GSW Worldwide/Junction 11 will be based in London and will maintain an office in Surrey, England, through early 2005. Clients include Eli Lilly, GlaxoSmithKline, Roche, Johnson & Johnson and Shire.
GSW Worldwide/Junction 11 will serve as the European hub for GSW Worldwide's global network, which includes affiliate agencies in 13 countries across the globe.
The new agency will employ approximately 25 people.  Senior leadership will include Richard Rayment and John Timney, formerly of Junction 11, who will serve as co-creative directors; and Richard Hart, formerly of Junction 11, who will serve as client services director.
Junction 11 founder John Greenwood will help manage the agency transition over the next several weeks, with a planned retirement at the end of the year.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.